288 related articles for article (PubMed ID: 24393214)
21. Desensitization for hypersensitivity reactions to medications.
del Carmen Sancho M; Breslow R; Sloane D; Castells M
Chem Immunol Allergy; 2012; 97():217-33. PubMed ID: 22613865
[TBL] [Abstract][Full Text] [Related]
22. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
[TBL] [Abstract][Full Text] [Related]
23. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
Nozawa H; Muto Y; Yamada Y
Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
[TBL] [Abstract][Full Text] [Related]
24. Are antineoplastic drug acute hypersensitive reactions a submerged or an emergent problem? Experience of the Medical Day Hospital of the Fondazione IRCCS Istituto Nazionale Tumori.
Ferrari LA; Fanetti G; Rossi FG; Brambilla MC; Re B; Buzzoni R
Tumori; 2014; 100(1):9-14. PubMed ID: 24675484
[TBL] [Abstract][Full Text] [Related]
25. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
[TBL] [Abstract][Full Text] [Related]
26. A new rapid desensitization protocol for chemotherapy agents.
Gastaminza G; de la Borbolla JM; Goikoetxea MJ; Escudero R; Antón J; Espinós J; Lacasa C; Fernández-Benítez M; Sanz ML; Ferrer M
J Investig Allergol Clin Immunol; 2011; 21(2):108-12. PubMed ID: 21462800
[TBL] [Abstract][Full Text] [Related]
27. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.
Gammon D; Bhargava P; McCormick MJ
Oncologist; 2004; 9(5):546-9. PubMed ID: 15477639
[TBL] [Abstract][Full Text] [Related]
28. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization.
Castells M; Sancho-Serra Mdel C; Simarro M
Cancer Immunol Immunother; 2012 Sep; 61(9):1575-84. PubMed ID: 22576054
[TBL] [Abstract][Full Text] [Related]
29. [Desensitisation to circumvent hypersensitivity reactions; treatment with docetaxel still possible].
Luiting J; de Monchy JG; Hiltermann TJ; Oude Elberink JN
Ned Tijdschr Geneeskd; 2011; 155():A2980. PubMed ID: 21527052
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
Park SJ; Lee KY; Park WS; Min SY
Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
[TBL] [Abstract][Full Text] [Related]
31. Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy.
Mezzano V; Giavina-Bianchi P; Picard M; Caiado J; Castells M
BioDrugs; 2014 Apr; 28(2):133-44. PubMed ID: 23990250
[TBL] [Abstract][Full Text] [Related]
32. Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children.
Hong DI; Dioun AF
J Allergy Clin Immunol Pract; 2014; 2(1):13-9; quiz 20. PubMed ID: 24565764
[TBL] [Abstract][Full Text] [Related]
33. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
34. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.
Jones R; Ryan M; Friedlander M
Gynecol Oncol; 2003 Apr; 89(1):112-5. PubMed ID: 12694663
[TBL] [Abstract][Full Text] [Related]
35. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.
Lafay-Cousin L; Sung L; Carret AS; Hukin J; Wilson B; Johnston DL; Zelcer S; Silva M; Odame I; Mpofu C; Strother D; Bouffet E
Cancer; 2008 Feb; 112(4):892-9. PubMed ID: 18098210
[TBL] [Abstract][Full Text] [Related]
36. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.
Banerji A; Lax T; Guyer A; Hurwitz S; Camargo CA; Long AA
J Allergy Clin Immunol Pract; 2014; 2(4):428-33. PubMed ID: 25017531
[TBL] [Abstract][Full Text] [Related]
37. Hypersensitivity reactions associated with oxaliplatin.
Saif MW
Expert Opin Drug Saf; 2006 Sep; 5(5):687-94. PubMed ID: 16907658
[TBL] [Abstract][Full Text] [Related]
38. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy.
Caiado J; Venemalm L; Pereira-Santos MC; Costa L; Barbosa MP; Castells M
J Allergy Clin Immunol Pract; 2013; 1(5):494-500. PubMed ID: 24565621
[TBL] [Abstract][Full Text] [Related]
39. Cross-sensitivity between taxanes in patients with breast cancer.
Sánchez-Muñoz A; Jiménez B; García-Tapiador A; Romero-García G; Medina L; Navarro V; González-Sánchez LA; Alba E
Clin Transl Oncol; 2011 Dec; 13(12):904-6. PubMed ID: 22126735
[TBL] [Abstract][Full Text] [Related]
40. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.
Sloane D; Govindarajulu U; Harrow-Mortelliti J; Barry W; Hsu FI; Hong D; Laidlaw T; Palis R; Legere H; Bunyavanich S; Breslow R; Wesemann D; Barrett N; Brennan P; Chong HJ; Liu A; Fernandez J; Fanning L; Kyin T; Cahill K; Bankova L; Lynch A; Berlin S; Campos S; Fuchs C; Mayer R; Matulonis U; Castells M
J Allergy Clin Immunol Pract; 2016; 4(3):497-504. PubMed ID: 26895621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
